Literature DB >> 25713967

Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis.

Theodore C Bailey1, Maria W Merritt, Fabrizio Tediosi.   

Abstract

It has been suggested that initiatives to eradicate specific communicable diseases need to be informed by eradication investment cases to assess the feasibility, costs, and consequences of eradication compared with elimination or control. A methodological challenge of eradication investment cases is how to account for the ethical importance of the benefits, burdens, and distributions thereof that are salient in people's experiences of the diseases and related interventions but are not assessed in traditional approaches to health and economic evaluation. We have offered a method of ethical analysis grounded in theories of social justice. We have described the method and its philosophical rationale and illustrated its use in application to eradication investment cases for lymphatic filariasis and onchocerciasis, 2 neglected tropical diseases that are candidates for eradication.

Entities:  

Mesh:

Year:  2015        PMID: 25713967      PMCID: PMC4358176          DOI: 10.2105/AJPH.2014.302454

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  59 in total

1.  A survey of treatment practices and burden of lymphoedema in Togo.

Authors:  Stephanie A Richard; Els Mathieu; David G Addiss; Yao K Sodahlon
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-11-16       Impact factor: 2.184

Review 2.  Onchocerciasis: the burden of disease.

Authors:  O O Kale
Journal:  Ann Trop Med Parasitol       Date:  1998-04

3.  Socio-cultural and behavioural aspects of mosquito-borne lymphatic filariasis in Thailand: a qualitative analysis.

Authors:  O Rauyajin; B Kamthornwachara; P Yablo
Journal:  Soc Sci Med       Date:  1995-12       Impact factor: 4.634

4.  Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India.

Authors:  K D Ramaiah; H Guyatt; K Ramu; P Vanamail; S P Pani; P K Das
Journal:  Trop Med Int Health       Date:  1999-01       Impact factor: 2.622

5.  The burden of hydrocele on men in Northern Ghana.

Authors:  M Gyapong; J Gyapong; M Weiss; M Tanner
Journal:  Acta Trop       Date:  2000-12-01       Impact factor: 3.112

6.  Stigma associated with onchocercal skin disease among those affected near the Ofiki and Oyan Rivers in western Nigeria.

Authors:  W R Brieger; F O Oshiname; O O Ososanya
Journal:  Soc Sci Med       Date:  1998-10       Impact factor: 4.634

7.  Socioeconomic consequences of blinding onchocerciasis in west Africa.

Authors:  T G Evans
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

Review 8.  Lymphatic filariasis and the women of India.

Authors:  L Bandyopadhyay
Journal:  Soc Sci Med       Date:  1996-05       Impact factor: 4.634

Review 9.  Social sciences research on infectious diseases of poverty: too little and too late?

Authors:  José Azoh Barry
Journal:  PLoS Negl Trop Dis       Date:  2014-06-12

10.  Marriage, sex, and hydrocele: an ethnographic study on the effect of filarial hydrocele on conjugal life and marriageability from Orissa, India.

Authors:  Bontha V Babu; Suchismita Mishra; Abhaya N Nayak
Journal:  PLoS Negl Trop Dis       Date:  2009-04-21
View more
  17 in total

1.  Characterizing "Civil Unrest" as a Public Health Determinant.

Authors:  Michael J DiStefano
Journal:  Am J Public Health       Date:  2018-07       Impact factor: 9.308

Review 2.  Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.

Authors:  Vadim Dukhanin; Alexandra Searle; Alice Zwerling; David W Dowdy; Holly A Taylor; Maria W Merritt
Journal:  Soc Sci Med       Date:  2017-12-14       Impact factor: 4.634

3.  Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for Trypanosoma brucei gambiense.

Authors:  Maria W Merritt; C Simone Sutherland; Fabrizio Tediosi
Journal:  Public Health Ethics       Date:  2018-07-18       Impact factor: 1.940

4.  Disadvantage and the Experience of Treatment for Multidrug-Resistant Tuberculosis (MDR-TB).

Authors:  Holly A Taylor; David W Dowdy; Alexandra R Searle; Andrea L Stennett; Vadim Dukhanin; Alice A Zwerling; Maria W Merritt
Journal:  SSM Qual Res Health       Date:  2022-01-28

5.  Towards equitable genomics governance in Africa: Guiding principles from theories of global health governance and the African moral theory of Ubuntu.

Authors:  Nchangwi Syntia Munung; Jantina de Vries; Bridget Pratt
Journal:  Bioethics       Date:  2022-01-18       Impact factor: 2.512

6.  Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.

Authors:  Christopher M Stone; Randee Kastner; Peter Steinmann; Nakul Chitnis; Marcel Tanner; Fabrizio Tediosi
Journal:  BMJ Glob Health       Date:  2016-04-06

7.  How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.

Authors:  Randee J Kastner; Elisa Sicuri; Christopher M Stone; Gabriel Matwale; Ambrose Onapa; Fabrizio Tediosi
Journal:  PLoS Negl Trop Dis       Date:  2017-09-26

8.  Exploring the ethics of global health research priority-setting.

Authors:  Bridget Pratt; Mark Sheehan; Nicola Barsdorf; Adnan A Hyder
Journal:  BMC Med Ethics       Date:  2018-12-06       Impact factor: 2.652

9.  Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa.

Authors:  Young Eun Kim; Elisa Sicuri; Fabrizio Tediosi
Journal:  PLoS Negl Trop Dis       Date:  2015-09-11

Review 10.  How can health systems research reach the worst-off? A conceptual exploration.

Authors:  Bridget Pratt; Adnan A Hyder
Journal:  BMC Health Serv Res       Date:  2016-11-15       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.